Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Trusheim

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Personalized Medicine|May 20, 2018
Economic challenges and possible policy actions to advance stratified medicineMark R Trusheim, Ernst R Berndt
Drug Discovery Today|November 7, 2015
The clinical benefits, ethics, and economics of stratified medicine and companion diagnosticsMark R Trusheim, Ernst R Berndt
Health Affairs (Project Hope)|September 8, 2021
Biosimilars And Follow-On Products: The Authors ReplyAriel D Stern, Mark R Trusheim
Drug Discovery Today|September 19, 2021
Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenuesColin M Young, Casey Quinn, Mark R Trusheim
JAMA|November 2, 2018
Alternative State-Level Financing for Hepatitis C Treatment-The "Netflix Model"Mark R Trusheim, William M Cassidy, Peter B Bach
Nature Reviews. Drug Discovery|March 24, 2007
Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkersMark R Trusheim, Ernst R Berndt, Frank L Douglas
Expert Review of Pharmacoeconomics & Outcomes Research|March 29, 2023
Value-based performance arrangements for chronic conditions: an economic simulation of Medicaid Drug Rebate Program reformsCasey Quinn, Michael Ciarametaro, Brian Sils, et al.
Pharmacogenomics|February 12, 2013
Uncertain prognosis for high-quality diagnostics: clinical challenges, economic barriers and needed reformsMark R Trusheim, M J Finley Austin, Carsten Rausch, et al.
Drug Discovery Today|November 20, 2025
The next decade in cell and gene therapySharon E Phares, Colin M Young, Katie I Phillip, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Comparison of Stakeholder Metrics for Traditional and Adaptive Development and Licensing Approaches to Drug DevelopmentLynn G Baird, Mark R Trusheim, Hans-Georg Eichler, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Personalized Medicine|May 20, 2018
Economic challenges and possible policy actions to advance stratified medicineMark R Trusheim, Ernst R Berndt
Drug Discovery Today|November 7, 2015
The clinical benefits, ethics, and economics of stratified medicine and companion diagnosticsMark R Trusheim, Ernst R Berndt
Health Affairs (Project Hope)|September 8, 2021
Biosimilars And Follow-On Products: The Authors ReplyAriel D Stern, Mark R Trusheim
Drug Discovery Today|September 19, 2021
Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenuesColin M Young, Casey Quinn, Mark R Trusheim
JAMA|November 2, 2018
Alternative State-Level Financing for Hepatitis C Treatment-The "Netflix Model"Mark R Trusheim, William M Cassidy, Peter B Bach
Nature Reviews. Drug Discovery|March 24, 2007
Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkersMark R Trusheim, Ernst R Berndt, Frank L Douglas
Expert Review of Pharmacoeconomics & Outcomes Research|March 29, 2023
Value-based performance arrangements for chronic conditions: an economic simulation of Medicaid Drug Rebate Program reformsCasey Quinn, Michael Ciarametaro, Brian Sils, et al.
Pharmacogenomics|February 12, 2013
Uncertain prognosis for high-quality diagnostics: clinical challenges, economic barriers and needed reformsMark R Trusheim, M J Finley Austin, Carsten Rausch, et al.
Drug Discovery Today|November 20, 2025
The next decade in cell and gene therapySharon E Phares, Colin M Young, Katie I Phillip, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Comparison of Stakeholder Metrics for Traditional and Adaptive Development and Licensing Approaches to Drug DevelopmentLynn G Baird, Mark R Trusheim, Hans-Georg Eichler, et al.
Pageof 2